Searched for
ARV BUSINESS
5 stocks with consistent score improvement and upside potential of up to 34% in 1 year, according to analystsGiven the current global and domestic situation, the chances are that the volatility quotient in the market will remain high. So, the best ...12 Oct, 2026, 03.24 PM IST- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...07 Oct, 2026, 05.28 PM IST
- Short-term headwind? Yes. But the structure stays intact: 5 large-cap stocks with upside potential of up to 19%Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is prob...15 Sep, 2026, 11.21 AM IST
- Laurus Labs shares nosedive 15% amid reports of US foreign aid suspensionLaurus Labs reported a 7% YoY drop in API revenues to Rs 531 crore for Q3 FY24, driven by lower ARV volumes. However, the FDF segment saw A...27 Jan, 2025, 01.44 PM IST
- Q1 Results Today: Laurus Labs, IEX and ACCLaurus Labs Q1 consolidated net profit fell 90% YoY to INR25 crore due to lower sales and elevated expenses. The API business reported a 2%...27 Jul, 2023, 04.39 PM IST
- Prices can’t go down further in APIs or it will turn unviable for new entrants: Laurus Labs CEO“If you look at the current nine months financials, the ARV APIs and formulation put together contributed only 35% of revenue came from ARV...31 Jan, 2023, 02.26 PM IST
- 3 reasons Laurus Labs is this week's stock pickLaurus Labs will benefit from the growth prospects of the global and domestic pharma indutry as spending on medicines, including Covid-19 v...27 Dec, 2022, 11.37 AM IST
- Laurus Labs net profit rises 15% to Rs 233 crore in Q2FY23The company had reported a net profit of Rs 202 crore during the same period of the previous year. On a quarter-on-quarter (QoQ) basis , th...21 Oct, 2022, 04.55 PM IST
- Laurus Labs Q3 results: Net profit drops 44% YoY to Rs 154 croreThe earnings before interest, tax, depreciation and amortization (EBITDA) decreased 17% YoY to Rs 290 crore. The EBITDA margins dropped by ...27 Jan, 2022, 04.40 PM IST
- Buy Laurus Lab, target price Rs 623: AmbitThere is high medium-term growth visibility and R&D spend commercialization would drive FY22 P/E re-rating from 13 times to 18 times on the...24 Mar, 2020, 10.36 AM IST
- Buy Laurus Labs, target Rs 535: HDFC SecuritiesBuy Laurus Labs at a price target of Rs 535.07 May, 2019, 03.38 PM IST
- Buy Laurus Labs, target Rs 470: Motilal Oswal SecuritiesBuy Laurus Labs at a price target of Rs 470.11 Apr, 2019, 01.49 PM IST
- Buy Laurus Labs, target Rs 480: HDFC SecuritiesBuy Laurus Labs at a price target of Rs 480.11 Jan, 2019, 06.05 PM IST
- Lauras Labs’ Q2 net up 1% on higher capexFor the quarter ended September 2017, the company posted a 4.3% growth in its revenues to Rs 538.6 crore as against Rs 516.5 crore in the c...10 Nov, 2017, 09.49 PM IST
- Sun Pharma may shed part of Ranbaxy business to push growthFaced with disappointing revenue and profit going forward, Sun Pharma is mulling options of exiting Ranbaxy's "low-margin" overseas geograp...22 Jul, 2015, 11.21 AM IST
- Sun Pharma may exit part of Ranbaxy business to push growthExiting the low-margin businesses may not result in a huge cash flow, but will improve the profitability of the company.22 Jul, 2015, 08.46 AM IST
- Indian firm sues South Africa after losing AIDS drug contractAn Indian manufacturer of drugs to treat HIV/AIDS is suing the South African government after failing to clinch a $400-million tender, Sout...29 Jun, 2009, 02.12 PM IST
Load More
